Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Keeps a healthy share of every dollar it sells.
- Revenue
- $4.60B
- Net income
- $940.8M
- Net margin
- 20.4%
A manageable debt load.
- Total debt
- $4.41B
- Cash
- $1.62B
- Net debt / EBITDA
- 1.70x
Comfortably covers what is due within a year.
- Current assets
- $3.97B
- Current liabilities
- $2.23B
- Current ratio
- 1.78
The business funds itself from operations.
- Operating cash flow
- $1.66B
- Free cash flow
- $1.54B
- FCF margin
- 33.5%
Not funding itself by issuing shares.
- Shares outstanding
- 63.2M
- Share growth (1y)
- 3.3%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
JAZZ Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 1.21 B | 1.07 B | 1.20 B | 1.13 B | 1.05 B | 897.84 M |
| Revenue Growth (YoY) | 15.55 % | 19.05 % | 10.09 % | 6.74 % | 2.14 % | -0.46 % |
| Cost of Revenue | 116.40 M | 306.40 M | 24.65 M | 257.76 M | 116.27 M | 104.62 M |
| Gross Profit | 1.09 B | 762.50 M | 1.17 B | 868.35 M | 929.44 M | 793.22 M |
| SG&A Expense | 389.20 M | 352.70 M | 406.21 M | 530.65 M | 358.40 M | 514.01 M |
| R&D Expense | 207.50 M | 134.10 M | 171.41 M | 240.70 M | 189.97 M | 180.65 M |
| Operating Expenses | 843.70 M | 548.70 M | 264.08 M | 810.84 M | 1.62 B | 849.11 M |
| Operating Income | 248.20 M | 213.80 M | 909.20 M | 57.51 M | -686.39 M | -55.89 M |
| Pretax Income | 211.00 M | 299.20 M | 208.28 M | 9.04 M | -735.55 M | -110.35 M |
| Tax Provision | 18.10 M | 6.10 M | 4.88 M | -242.42 M | -17.08 M | -17.81 M |
| Net Income | 192.80 M | 293.10 M | 203.45 M | 251.41 M | -718.47 M | -92.54 M |
| EPS (Basic) | 3.05 | 4.73 | 3.28 | 4.14 | -11.74 | -1.52 |
| EPS (Diluted) | 2.78 | 4.43 | 3.34 | 4.08 | -11.74 | -1.52 |
| Shares Outstanding | 63.20 M | 61.90 M | 60.98 M | 60.70 M | 61.19 M | 60.98 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.